References
- DeVita VT, Lawrence TS, Rosenberg, SA, (Eds) DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology, 9th Edition. Philadelphia, PA: Lippincott Williams & Wilkins, 2011
- Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R, Escara-Wilke J, Wilder-Romans K, Dhanireddy S, Engelke C, et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 2014; 510:278-82; PMID: 24759320; http://dx.doi.org/10.1038/nature13229
- Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C, Smith S, Scher H, Scardino P, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004; 164:217-27; PMID:14695335; http://dx.doi.org/10.1016/S0002-9440(10)63112-4
- Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005; 23(32):8253; PMID:16278481; http://dx.doi.org/10.1200/JCO.2005.03.4777
- Pazdur R. FDA Approval for Abiraterone Acetate. National Cancer Institute website. Available from http://www.cancer.gov/cancertopics/druginfo/fda-abirateroneacetate
- Stein MN, Goodin S, DiPaola RS. Abiraterone in prostate cancer: a new angle to an old problem. Clin Cancer Res 2012; 18:1848-54; PMID:22451619; http://dx.doi.org/10.1158/1078-0432.CCR-11-1805
- Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367:1187-97; PMID:22894553; http://dx.doi.org/10.1056/NEJMoa1207506
- Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371:424-33; PMID:24881730; http://dx.doi.org/10.1056/NEJMoa1405095
- Rahman S, Sowa ME, Ottinger M, Smith JA, Shi Y, Harper JW, Howley PM. The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3. Mol Cell Biol 2011; 31(13):2641; PMID: 21555454; http://dx.doi.org/10.1128/MCB.01341-10
- Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, et al. Selective inhibition of BET bromodomains. Panagis filippakopoulos, Nature 2010; 468:1067-73; PMID: 20871596; http://dx.doi.org/10.1038/nature09504
- Seton-Rogers S. BETting on epigenetic therapy. Nat Rev Cancer 2014; 14:384-5; PMID:24827504; http://dx.doi.org/10.1038/nrc3750